Blueshift Asset Management LLC acquired a new position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,228 shares of the medical equipment provider’s stock, valued at approximately $231,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. boosted its position in Zimmer Biomet by 35.3% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 11,938 shares of the medical equipment provider’s stock valued at $1,569,000 after buying an additional 3,115 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Zimmer Biomet in the 3rd quarter valued at about $1,456,000. Penserra Capital Management LLC boosted its position in Zimmer Biomet by 16.5% in the 3rd quarter. Penserra Capital Management LLC now owns 3,128 shares of the medical equipment provider’s stock valued at $411,000 after buying an additional 442 shares during the last quarter. Achmea Investment Management B.V. boosted its position in Zimmer Biomet by 127.1% in the 3rd quarter. Achmea Investment Management B.V. now owns 9,772 shares of the medical equipment provider’s stock valued at $1,283,000 after buying an additional 5,469 shares during the last quarter. Finally, Stone Ridge Asset Management LLC boosted its position in Zimmer Biomet by 18.1% in the 3rd quarter. Stone Ridge Asset Management LLC now owns 4,449 shares of the medical equipment provider’s stock valued at $585,000 after buying an additional 683 shares during the last quarter. 90.25% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE ZBH opened at $122.94 on Friday. The company has a current ratio of 1.83, a quick ratio of 0.91 and a debt-to-equity ratio of 0.75. Zimmer Biomet Holdings Inc has a 52-week low of $96.99 and a 52-week high of $134.55. The stock has a market capitalization of $25.08 billion, a price-to-earnings ratio of 16.09, a price-to-earnings-growth ratio of 2.20 and a beta of 1.23.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.78%. Zimmer Biomet’s dividend payout ratio is currently 12.57%.
In other Zimmer Biomet news, Director Syed A. Jafry bought 1,925 shares of the business’s stock in a transaction on Friday, March 1st. The shares were purchased at an average price of $125.52 per share, with a total value of $241,626.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Betsy J. Bernard bought 4,250 shares of the business’s stock in a transaction on Wednesday, February 6th. The stock was acquired at an average cost of $117.41 per share, for a total transaction of $498,992.50. Following the acquisition, the director now directly owns 2,000 shares of the company’s stock, valued at $234,820. The disclosure for this purchase can be found here. Insiders acquired 12,860 shares of company stock worth $1,548,994 in the last three months. 0.71% of the stock is currently owned by corporate insiders.
A number of research firms have weighed in on ZBH. Morgan Stanley upped their price objective on shares of Zimmer Biomet from $132.00 to $143.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Barclays set a $113.00 price target on shares of Zimmer Biomet and gave the stock a “sell” rating in a research report on Tuesday, February 5th. SunTrust Banks increased their price target on shares of Zimmer Biomet to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, February 5th. TheStreet cut shares of Zimmer Biomet from a “b-” rating to a “c” rating in a research report on Friday, February 1st. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Saturday, February 2nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the company. Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $128.33.
ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4222573/blueshift-asset-management-llc-takes-231000-position-in-zimmer-biomet-holdings-inc-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Read More: How dollar cost averaging works
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.